Clinical Trials Logo

Leukemia, Acute Myeloid (AML) clinical trials

View clinical trials related to Leukemia, Acute Myeloid (AML).

Filter by:
  • None
  • Page 1

NCT ID: NCT05586074 Recruiting - Clinical trials for Leukemia, Acute Myeloid (AML)

HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

Start date: March 3, 2023
Phase: Phase 3
Study type: Interventional

A randomized,multicenter, open-label Phase III, clinical study is conducted to evaluate the clinical benefit Clifutinib in Chinese patients with relapsed/ refractory (R/R) FLT3-mutated AML as shown with overall survival compared to salvage chemotherapy, and also to investigate the efficacy of Clifutinib as assessed by CR/CRh rate in these subjects.

NCT ID: NCT02421939 Active, not recruiting - Clinical trials for Leukemia, Acute Myeloid (AML)

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Start date: October 20, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who are refractory to or have relapsed after first-line AML therapy as shown with overall survival (OS) compared to salvage chemotherapy, and to determine the efficacy of ASP2215 therapy as assessed by the rate of complete remission and complete remission with partial hematological recovery (CR/CRh) in these participants. This study will also determine the overall efficacy in event-free survival (EFS) and complete remission (CR) rate of ASP2215 compared to salvage chemotherapy.

NCT ID: NCT01810120 Completed - Clinical trials for Myelodysplastic Syndromes

Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT

Start date: January 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Allocation: Non-Randomized Endpoint Classification: Safety/Feasibility Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment Study to assess the feasibility and safety of the infusion of a T cells receptor (TCR) alfa beta depleted graft in pediatric patients affected by malignant and non-malignant hematological disorders and receiving an Hematopoietic stem cell transplantation (HSCT) from a Human leukocyte antigen (HLA) partially matched family donor.